- Home
- KINS vs RCKT Comparison
KINS vs RCKT Comparison
Compare KINS & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KINS | RCKT |
|---|---|---|
| Founded | 1886 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.5M | 239.3M |
| IPO Year | 2013 | 2014 |
Fundamental Metrics
Financial Performance| Metric | KINS | RCKT |
|---|---|---|
| Price | $20.10 | $2.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $8.58 |
| AVG Volume (30 Days) | 57.8K | ★ 2.1M |
| Earning Date | 11-05-2026 | 11-13-2026 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | ★ 94.59 | 26.37 |
| EPS | 0.66 | 0.66 |
| Revenue | ★ $214,867,301.00 | N/A |
| Revenue This Year | $18.83 | N/A |
| Revenue Next Year | $15.85 | $915.60 |
| P/E Ratio | $30.33 | ★ $3.85 |
| Revenue Growth | ★ 38.50 | N/A |
| 52 Week Low | $13.83 | $2.17 |
| 52 Week High | $20.90 | $5.45 |
Technical Indicators
Market Signals| Indicator | KINS | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 62.39 | 45.08 |
| Support Level | $18.52 | $2.17 |
| Resistance Level | $20.52 | $2.78 |
| Average True Range (ATR) | 0.47 | 0.18 |
| MACD | 0.13 | 0.06 |
| Stochastic Oscillator | 90.55 | 53.47 |
Price Performance
Historical ComparisonAbout KINS Kingstone Companies Inc.
Kingstone Companies Inc offers property and casualty insurance products through its subsidiary engaged in writing business through retail and wholesale agents and brokers. Its products include Personal lines, Livery physical damage, and Others. It operates in single segment, property and casualty insurance. It derives substantially all of its revenue from KICO, including revenues from earned premiums, ceding commissions from quota share reinsurance, net investment income generated from its investment portfolio, and net realized gains and losses on investment securities.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.